Monia Garofolo, Giuseppe Penno, Anna Solini, Emanuela Orsi, Martina Vitale, Veronica Resi, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato, Antonio Nicolucci, Giuseppe Pugliese, Renal Insufficiency And Cariovascular Events (RIACE) Study Group
{"title":"2型糖尿病患者蛋白尿正常范围内与全因死亡率的关系","authors":"Monia Garofolo, Giuseppe Penno, Anna Solini, Emanuela Orsi, Martina Vitale, Veronica Resi, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato, Antonio Nicolucci, Giuseppe Pugliese, Renal Insufficiency And Cariovascular Events (RIACE) Study Group","doi":"10.1002/dmrr.70061","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>To investigate the independent association of albuminuria within the normoalbuminuric range with all-cause mortality in normoalbuminuric people with type 2 diabetes with and without chronic kidney disease (CKD).</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>This observational, prospective, multicentre, cohort study enroled 15,773 individuals with type 2 diabetes in 2006–2008. At baseline, albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR) were assessed together with cardiometabolic risk profile, treatments, complications, and comorbidities. All-cause mortality was verified on 31 October 2015.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 15,656 participants (99.3%) with valid information on vital status, 11,460 (71.2%) were normoalbuminuric, 9984 (87.1%) without and 1476 (12.9%) with CKD. Normoalbuminuric individuals were stratified into three (< 5, 5–15, and > 15 mg·day<sup>−1</sup>) or two (< 10 and 10–29 mg·day<sup>−1</sup>) AER subcategories. When adjusting for age, sex, eGFR, prior cardiovascular disease, cardiovascular risk factors, and treatments, mortality risk was higher in participants with AER 10–29 versus < 10 mg·day<sup>−1</sup> (hazard ratio, 1.120 [95% confidence interval, 1.028–1.221], <i>p</i> = 0.009) and 15–29 versus < 5 mg·day<sup>−1</sup> (1.243 [1.099–1.406], <i>p</i> < 0.0001). When stratifying by CKD status, the adjusted risk remained significantly increased only for AER 15–29 versus < 5 mg/24 h in individuals with (1.404 [1.111–1.774], <i>p</i> = 0.005) and, to a lesser extent, without (1.167 [1.009–1.350], <i>p</i> = 0.038) CKD. A non-linear association was observed between AER as Log2 transformed continuous variable and mortality.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>For the same level of kidney function, higher AER within the normoalbuminuric range was independently associated with all-cause mortality, thus supporting to the use of albuminuria-lowering drugs in people with type 2 diabetes and mildly elevated albuminuria.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 5","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70061","citationCount":"0","resultStr":"{\"title\":\"Association of Albuminuria Within the Normoalbuminuric Range With All-Cause Mortality in People With Type 2 Diabetes\",\"authors\":\"Monia Garofolo, Giuseppe Penno, Anna Solini, Emanuela Orsi, Martina Vitale, Veronica Resi, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato, Antonio Nicolucci, Giuseppe Pugliese, Renal Insufficiency And Cariovascular Events (RIACE) Study Group\",\"doi\":\"10.1002/dmrr.70061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>To investigate the independent association of albuminuria within the normoalbuminuric range with all-cause mortality in normoalbuminuric people with type 2 diabetes with and without chronic kidney disease (CKD).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>This observational, prospective, multicentre, cohort study enroled 15,773 individuals with type 2 diabetes in 2006–2008. At baseline, albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR) were assessed together with cardiometabolic risk profile, treatments, complications, and comorbidities. All-cause mortality was verified on 31 October 2015.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Of the 15,656 participants (99.3%) with valid information on vital status, 11,460 (71.2%) were normoalbuminuric, 9984 (87.1%) without and 1476 (12.9%) with CKD. Normoalbuminuric individuals were stratified into three (< 5, 5–15, and > 15 mg·day<sup>−1</sup>) or two (< 10 and 10–29 mg·day<sup>−1</sup>) AER subcategories. When adjusting for age, sex, eGFR, prior cardiovascular disease, cardiovascular risk factors, and treatments, mortality risk was higher in participants with AER 10–29 versus < 10 mg·day<sup>−1</sup> (hazard ratio, 1.120 [95% confidence interval, 1.028–1.221], <i>p</i> = 0.009) and 15–29 versus < 5 mg·day<sup>−1</sup> (1.243 [1.099–1.406], <i>p</i> < 0.0001). When stratifying by CKD status, the adjusted risk remained significantly increased only for AER 15–29 versus < 5 mg/24 h in individuals with (1.404 [1.111–1.774], <i>p</i> = 0.005) and, to a lesser extent, without (1.167 [1.009–1.350], <i>p</i> = 0.038) CKD. A non-linear association was observed between AER as Log2 transformed continuous variable and mortality.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>For the same level of kidney function, higher AER within the normoalbuminuric range was independently associated with all-cause mortality, thus supporting to the use of albuminuria-lowering drugs in people with type 2 diabetes and mildly elevated albuminuria.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11335,\"journal\":{\"name\":\"Diabetes/Metabolism Research and Reviews\",\"volume\":\"41 5\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70061\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes/Metabolism Research and Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70061\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70061","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Association of Albuminuria Within the Normoalbuminuric Range With All-Cause Mortality in People With Type 2 Diabetes
Aims
To investigate the independent association of albuminuria within the normoalbuminuric range with all-cause mortality in normoalbuminuric people with type 2 diabetes with and without chronic kidney disease (CKD).
Materials and Methods
This observational, prospective, multicentre, cohort study enroled 15,773 individuals with type 2 diabetes in 2006–2008. At baseline, albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR) were assessed together with cardiometabolic risk profile, treatments, complications, and comorbidities. All-cause mortality was verified on 31 October 2015.
Results
Of the 15,656 participants (99.3%) with valid information on vital status, 11,460 (71.2%) were normoalbuminuric, 9984 (87.1%) without and 1476 (12.9%) with CKD. Normoalbuminuric individuals were stratified into three (< 5, 5–15, and > 15 mg·day−1) or two (< 10 and 10–29 mg·day−1) AER subcategories. When adjusting for age, sex, eGFR, prior cardiovascular disease, cardiovascular risk factors, and treatments, mortality risk was higher in participants with AER 10–29 versus < 10 mg·day−1 (hazard ratio, 1.120 [95% confidence interval, 1.028–1.221], p = 0.009) and 15–29 versus < 5 mg·day−1 (1.243 [1.099–1.406], p < 0.0001). When stratifying by CKD status, the adjusted risk remained significantly increased only for AER 15–29 versus < 5 mg/24 h in individuals with (1.404 [1.111–1.774], p = 0.005) and, to a lesser extent, without (1.167 [1.009–1.350], p = 0.038) CKD. A non-linear association was observed between AER as Log2 transformed continuous variable and mortality.
Conclusions
For the same level of kidney function, higher AER within the normoalbuminuric range was independently associated with all-cause mortality, thus supporting to the use of albuminuria-lowering drugs in people with type 2 diabetes and mildly elevated albuminuria.
期刊介绍：
Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
